The incidence of specific toxicities such as hypertension (6.3%-vs-25%, p = NS) and sudden cardiac arrest/death (0%-vs-1.5%, p = NS) were lower in the acalabrutinib group compared to ibrutinib; however, these did not reach statistical significance.
← all excerpts
Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)-an analysis of an administrative health claims database.
1
—
—